Testing partial thyroid removal with heat treatment for thyroid cancer in both lobes
Tests partial thyroid removal and heat ablation in adults with thyroid cancer.
Plain-language title generated from the registry record
Registry title: Hybrid Endoscopic Hemithyroidectomy and Targeted Ablation for Bilateral Papillary Thyroid Carcinoma
Key facts
- Where
- Fuzhou, ChinaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Source: NCT07033572, who can take part
Where in China
- Fujian Medical University Union HospitalFuzhou, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Fujian Medical University
- Trial code
- NCT07033572
- Record updated
- 3 July 2025
- Original description
This study evaluates a thyroid-function-preserving alternative to routine total thyroidectomy for bilateral papillary thyroid carcinoma (PTC). Eligible adults undergo remote-access gas-less axillo-breast endoscopic hemithyroidectomy with level VI dissection on the dominant side, followed by ultrasound-guided radiofrequency ablation (RFA) of a ≤7 mm contralateral focus during the same anesthesia. Outcomes include structural-recurrence-free survival, endocrine-function preservation, safety, and quality of life over 24 months.Read full original descriptionShow less
Hybrid Endoscopic Hemithyroidectomy and Targeted Ablation for Bilateral Papillary Thyroid Carcinoma
This study evaluates a thyroid-function-preserving alternative to routine total thyroidectomy for bilateral papillary thyroid carcinoma (PTC). Eligible adults undergo remote-access gas-less axillo-breast endoscopic hemithyroidectomy with level VI dissection on the dominant side, followed by ultrasound-guided radiofrequency ablation (RFA) of a ≤7 mm contralateral focus during the same anesthesia. Outcomes include structural-recurrence-free survival, endocrine-function preservation, safety, and quality of life over 24 months.
Inclusion: Age 18-65 years; Dominant-side PTC ≤1.5 cm suitable for endoscopic resection; Contralateral nodule ≤7 mm located ≥2 mm from posterior capsule; No radiologic lymph-node metastasis on contralateral side; Written informed consent.
Exclusion: Prior neck surgery, prior RFA/ethanol injection, or neck irradiation; Extrathyroidal extension, gross nodal or distant metastasis; Pregnancy or lactation; Serious comorbidities precluding anesthesia or follow-up.